The thread introduces CBL-514 as an injectable small-molecule lipolysis agent focused on subcutaneous abdominal fat via adipocyte apoptosis. Participants note it differs from tesamorelin which targets visceral fat, discuss its Phase 3 status and proprietary nature, and speculate on sourcing, side-effect profile relative to growth-hormone secretagogues, and possible metabolic benefits. No one confirms current grey-market availability and several express interest in further data on safety and combinations.
What this discussion establishesWhether CBL-514 is obtainable outside official trials and what its full safety profile looks like compared with existing peptides
Nothing here is advice.
There's this new injectable called CBL-514 that could work well and safely for cutting localized fat under the skin in the belly area.
I'd like to see the specific articles or links you've come across on it. Google works but I'd rather know what caught your eye instead of whatever the search engine pushes. Tesamorelin probably isn't disappearing though. You mentioned CBL-514 hits subcutaneous fat while tesamorelin goes after visceral fat. Stacking them might carry risks but it could also leave someone looking pretty gaunt.
Can you say more about the safety angle? The main worries I have with starting tesamorelin are swelling plus higher cortisol and prolactin. The regulators will be busy if they try to ban every peptide one by one instead of a blanket rule. I hope they can't just wipe out everything that exists or gets made. It would be good if new versions keep getting created with small tweaks so the effects stay similar.
Can you even get CBL-514 yet through unofficial channels?
I only just started looking into it after seeing this. My guess is that if it's not out there now it will be before long. The safety details interest me most, especially if it behaves like the growth-hormone releasing peptides.
It's not actually a peptide. It's a small molecule so it tends to be tougher to source.
It's described as a proprietary small-molecule drug in Phase 3 trials held by a public company. Close enough to the usual channels for now.
I'd need to look things up again so take this with that in mind, but it seems built around curcumin and resveratrol in roughly a four-to-one mix and no public formula is out there. That could explain why it hasn't shown up much in unofficial markets. One animal study hinted it might help with visceral and liver fat plus some metabolic markers. Another suggested less weight regain after stopping GLP-1 drugs if this was used at the same time. It appears gentler than deoxycholate versions on subcutaneous fat and I haven't located anyone making the exact mix.
From what I saw quickly it's meant for spot reduction of subcutaneous fat rather than visceral, so it's quite different from tesamorelin. The description says it triggers fat-cell death in targeted areas without skin necrosis, ulcers, nerve damage or widespread side effects.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.